secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001104659-26-017546
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics reports FY2025 product/royalty rev $831M, beats guidance; Sephience Q4 rev $92M
--------------------------------------------------------------------------------

- Full-year 2025 product/royalty revenue $831M, exceeding guidance; total revenue $1.73B (includes $998M Novartis collaboration).
- Sephience launch strong: Q4 rev $92M ($81M US), 946 patients on therapy; full-year rev $111M.
- Net income $682.6M for FY2025 vs net loss $363.3M in FY2024; cash $1.95B as of Dec 31.
- Sold Evrysdi royalty to Royalty Pharma for $240M upfront + up to $60M milestones; retains $150M Roche milestone.
- 2026 guidance: product rev $700-800M (19-36% growth); Phase 3 HD trial INVEST-HD to start 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/0001104659-26-017546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926017546/tmb-20260219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-017546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer